Long-term effects of cancer treatment and consequences of cure: Cancer survivors enjoy quality of life similar to their neighbours

Olweny, Charles L. M.; Juttner, Christopher A.; Rofe, Peter B.; Barrow, Graham; Esterman, Adrian; Waltham, Robert; Abdi, Ehtesham; H, Chesterman; Seshadri, Ram; Sage, Edward; Andary, Carol; Katsikitis, Mary; Roberts, Marion; Selva-Nayagam, Sid

doi:10.1016/s0959-8049(05)80418-6

Cited by 28 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have been seen with long-term survivors of other cancers. 12 The current findings are important insofar as patients showed normal mental quality of life at baseline and during only two-year follow-up, before long-term survival was assured. Ulander et al 13 reported on a cohort of 86 patients with colorectal cancer and found that emotional functioning, appetite, and global quality of life was higher at five to eight month's follow-up than preoperatively.…”

Section: Mental Quality Of Lifementioning

confidence: 64%

Patient Satisfaction and Health-Related Quality of Life After Treatment for Colon Cancer

Gall¹,

Weller²,

Esterman³

et al. 2007

Diseases of the Colon &Amp; Rectum

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Mental Quality Of Lifementioning

confidence: 64%

Patient Satisfaction and Health-Related Quality of Life After Treatment for Colon Cancer

Gall¹,

Weller²,

Esterman³

et al. 2007

Diseases of the Colon &Amp; Rectum

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although we did not specifically examine recall, these data would support the findings of others (Ley and Spelman, 1967), that in most groups of patients that less than half the information given was later recalled. Penman et al (1984) (Fobair et al, 1986;Newall et al, 1987;Bloom et al, 1993;Olweny et al, 1993;Zeltzer, 1993) have examined the adaption of survivors of Hodgkin's disease and stress the importance of quality survival from both psychological and physical points of view. The emphasis in this study was to investigate the relative importance of different morbidities to give guidance to the content of initial information 'packages'.…”

Section: Information and Involvementmentioning

confidence: 99%

What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease

Turner

Maher²,

Young³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary A total of 165 adult patients with Hodgkin's disease (HD) were questioned following treatment to examine their perceptions of actual and desired involvement and provision of information in the treatment decision-making process. Irrespective of the degree to which patients felt they had been involved in the decision-making process and of the outcome of their particular treatment, patients who felt satisfied with the adequacy of information given were significantly more likely to feel happy with their level of participation in the overall process of decision-making (P<0.001). As part of a strategy investigating patient priorities, patients were asked to rank a series of possible acute and late treatment-related morbidities. Counterintuitively, the majority of long-term survivors felt early short-term side-effects were more, or equally, as important as late morbidity with respect to influencing choice of therapy. 165/230 (72%).Sixty-eight of the patients who replied were female and 97 were male. The median age of patients at the time of first treatment was 28 years (range 18-50 years) and the median interval from initial treatment to completing the questionnaire was 8 years (range 0-22 years).The first part of the first questionnaire dealt with patients' perceptions of the initial decision-making process, in particular the extent to which patients remembered feeling involved in decisions regarding their treatment, their satisfaction with this level of involvement and the provision of information about the disease and therapy options. The types of treatment experienced by that patient were recorded and if they had received both chemotherapy and radiotherapy, they were asked their overall impression of which treatment was most difficult.The second section aimed to identify disease and treatment morbidities (both early and late) that patients felt were the most important discriminants between different therapy options. Patients were asked to specify which of a list of symptoms or problems they had suffered during treatment and in the years after treatment. They were asked to rank all side-effects listed in order of importance with regard to the degree they would influence a future decision regarding cancer treatment. Patients were asked to rank all side-effects in this way whether they had experienced them or not.

show abstract

“…In a controlled study of 522 men, satisfaction with sexual life was found to be a powerful predictor of satisfaction with life as a whole [32]. Similarly, among cancer survivors, a QOL study concluded that cancer survivors enjoy QOL similar to their noncancer counterparts in all but one aspect of daily life: sexual functioning [33].…”

Section: Discussionmentioning

confidence: 98%

Randomized, Double-Blinded, Placebo-Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Short-Term Androgen Deprivation Therapy: Results of RTOG 0215

Bruner

James

Bryan

et al. 2011

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) may be the most commonly observed adverse event (AE) associated with the combination of radiation therapy (RT) and androgen deprivation therapy (ADT). A significant number of men are trying phosphodiesterase type 5 inhibitors (PDE5s) such as sildenafil to treat ED, yet sildenafil studies to date shed little light on the response to ED after ADT. Aim The purpose of this trial was to evaluate sildenafil in the treatment of ED in prostate cancer patients previously treated with external beam RT and neoadjuvant and concurrent ADT. Methods In this randomized, double-blinded crossover trial, eligible patients received RT/ADT for intermediate risk prostate cancer and currently had ED as defined by the International Index of Erectile Function (IIEF). Patients were randomized to 12 weeks of sildenafil or placebo followed by 1 week of no treatment then 12 weeks of the alternative. Treatment differences were evaluated using a marginal model for binary crossover data. Main Outcome Measures The primary end point was improved erectile function, as measured by the IIEF. Results The study accrued 115 patients and 61 (55%) completed all three IIEF assessments. Sildenafil effect was significant (P = 0.009) with a difference in probabilities of erectile response of 0.17 (95% confidence interval: 0.06, 0.29), and 0.21 (0.06, 0.38) for patients receiving ≤120 days of ADT. However, as few as 21% of patients had a treatment-specific response, only improving during sildenafil but not during the placebo phase. Conclusions This is the first controlled trial to suggest a positive sildenafil response for ED treatment in patients previously treated with RT/ADT, however, only a minority of patients responded to treatment. ADT duration may be associated with response and requires further study. The overall low response rate suggests the need for study of additional or preventative strategies for ED after RT/ADT for prostate cancer.

show abstract

Long-term effects of cancer treatment and consequences of cure: Cancer survivors enjoy quality of life similar to their neighbours

Cited by 28 publications

References 27 publications

Patient Satisfaction and Health-Related Quality of Life After Treatment for Colon Cancer

Patient Satisfaction and Health-Related Quality of Life After Treatment for Colon Cancer

What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease

Randomized, Double-Blinded, Placebo-Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Short-Term Androgen Deprivation Therapy: Results of RTOG 0215

Contact Info

Product

Resources

About